News & Updates

Real Endpoints Recent Developments

PCSK9 Sponsors, Payers In The Ring At ACC

Posted by Cam Woods on Thursday, April 14, 2016

Cardiologists bemoaned high cost of new drugs and high hurdles for reimbursement at the American College of Cardiology annual meeting; will outcomes data save the day?

Learn More

How Can Migraine Drugmakers Avoid the PCSK9 Debacle?

Posted by Cam Woods on Friday, April 8, 2016

One of the big ideas in biotech today is that you can prevent severe, chronic migraine headaches. This story has a lot of juicy ingredients: intriguing biology, bona fide medical value, and a potentially broad impact on millions of people.

Learn More

Medicaid May Offer Best Opportunity For Merck’s Zepatier

Posted by Cam Woods on Wednesday, April 6, 2016

Newest hepatitis C entrant doesn’t have the best value in all subpopulations, according to analysis by RealEndpoints, but Medicaid’s mandatory discount could make up for those disadvantages.

Learn More

Forbes names Real Endpoints CEO, Roger Longman, to pricing dream team

Posted by Julie Eagle on Friday, March 25, 2016

Forbes, Pharma & Healthcare, March 24, 2016 by Luke Timmerman

The Dream Team That Could Fix Drug Pricing

Please click here to read full article.

Learn More

A tale of two new hepatitis C drugs

Posted by Julie Eagle on Thursday, March 10, 2016

Despite discount, Merck’s just approved Zepatier unlikely to win share with most US payers, except in Medicaid, according to RxScorecard™.
New combo from Gilead could ensure company’s dominant position among US payers.

Learn More

Real Endpoints’ RxScorecard™ predicted launch failure of major new anti-cholesterol drugs

Posted by Julie Eagle on Thursday, February 11, 2016

Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened.

Learn More